NEW YORK (GenomeWeb) – OncoDNA today announced a distribution deal with Malaysian oncology firm Genesis Genome to bring affordable theranostic analysis to that country.
Under the terms of the deal, Genesis Genome has selected OncoDNA as its exclusive supplier of clinical grade molecular theranostics and will make available to Malaysian physicians OncoDNA's OncoDeep DX and OncoDeep Clinical cancer panels combined with its Package Plus, enabling clinically relevant interpretations of patients' tumors using the OncoShare web platform.
OncoDeep DX comprises 65 genes while the OncoDeep Clinical cancer panel comprises 409 genes. Package Plus is made up of immunohistochemistry and other tests to analyze the presence of key proteins and activity and translocations.
Financial and other terms of the deal were not disclosed.